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Abstract 
Purpose:  Pre-existing diabetes is associated with increased morbidity and mortality in cancer, 
but there is less information on how cancer impacts diabetes outcomes.  We examined the 
impact of incident cancer on long-term outcomes of diabetes.  Methods: Using the United 
Kingdom Clinical Practice Research Datalink, we identified three cohorts of diabetes patients 
subsequently diagnosed with breast, colorectal, or prostate cancer, who were matched to 
diabetic non-cancer controls on age, sex, and general practice identification number.  Patients 
were required to have survived at least one year after cancer diagnosis (cases) or a matched 
index date (controls), and were followed up to 10 years for incident microvascular (chronic 
kidney disease, nephropathy, neuropathy, retinopathy) and macrovascular (acute myocardial 
infarction, cerebrovascular accident, lower limb amputation, and peripheral arterial disease) 
complications, and mortality.  Multivariate competing risks regression analyses were used to 
compare outcomes between cancer patients and controls.  Results:  Overall, there were 3,382 
cancer patients and 11,135 controls with 59,431 person-years of follow-up.  In adjusted 
analyses, there were no statistically significant (p≤0.05) differences in diabetes complication 
rates between cancer patients and their controls in any of the three cancer cohorts.  Combined, 
cancer patients were less likely (adjusted Hazard Ratio [HR] 0.88; 95%CI=0.79-0.98) to develop 
retinopathy.  Cancer patients were more likely to die of any cause (including cancer), but 
prostate cancer patients were less likely to die of causes associated with diabetes (HR 0.61: 
95%CI=0.43-0.88).  Conclusions and Implications: There is no evidence that incident cancer had 
an adverse impact on the long-term outcomes of pre-existing diabetes. These findings are 
important for cancer survivors with pre-existing diabetes because they suggest that advances in 
cancer therapy and supportive care, which have substantially improved the relative survival of 
many of the most common types of cancer, are not undermined by excess diabetes morbidity 
and mortality. 
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Introduction 
Evidence from epidemiologic studies, as summarized in a number of recent reviews, (1-10) 
indicates pre-existing diabetes is associated with worse short and long-term outcomes of 
cancer, both overall (9,10), and in specific types of cancer including breast, (3,4,10) colorectal, 
(2,3,4-7,10) and prostate. (8)  There are several reasons why the converse also may be true—
that incident cancer adversely impacts the outcomes of pre-existing diabetes.  Potential 
mechanisms include adverse effects of cancer treatments on glycemic control, (11,12) the 
impact of cancer on patient self-management of diabetes, (13) and changes in the quality of 
diabetes primary care services during cancer treatment and follow-up. (14-19) However, there 
is considerably less information on how cancer impacts the long-term outcomes of pre-existing 
diabetes. (12, 20) 
This gap in our understanding of how cancer impacts pre-existing diabetes is important from 
several perspectives.  For instance, as early detection and advances in cancer therapy and 
supportive care have substantially improved the relative survival of many of the most common 
types of cancer, (21) overall morbidity and mortality in cancer depend increasingly on the 
quality and outcomes of primary care for other underlying conditions (22).  In response, cancer 
organizations, such as Cancer Research UK and Macmillan Cancer Support in the United 
Kingdom (UK), have expressed concern that overlooking other medical conditions during cancer 
treatment and follow-up could result in excess morbidity and mortality, thereby undermining 
gains associated with early detection and treatment of cancer. (23,24) 
The objective of this study was to examine the effect of cancer on the long-term outcomes of 
pre-existing diabetes. 
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Methods 
Study Design and Data Source 
We conducted an historical cohort study using the UK Clinical Practice Research Datalink (CPRD) 
linked to Office for National Statistics (ONS) mortality data.  The CPRD contains anonymised 
information from general practitioner (GP) practices on demographics, symptoms, tests, 
diagnoses, therapies, health-related behaviours, and referrals to secondary care for over 11.3 
million patients from 674 practices in the UK. (25) There are 4.4 million active (alive, currently 
registered) patients in the database, which is approximately 6.9% of the UK population.  These 
patients are broadly representative of the UK general population in terms of age, sex, and 
ethnicity. (25)  This database (including its predecessor, the General Practice Research Datalink) 
has been used extensively for health services and epidemiologic research in cancer and 
diabetes. (26-30) 
Patient Selection 
Using CPRD, we identified three cohorts of cancer patients with pre-existing diabetes, each 
matched to diabetic non-cancer controls.  Cancer patients (cases) were included if they met all 
of the following criteria: (A) diagnosed with breast, colorectal, or prostate cancer on or after  
January 1st, 2000; (B) diagnosed with type I or type II diabetes at least two years before their 
date of cancer diagnosis (index date); (C) had no other cancer diagnosis, except non-melanoma 
skin cancer, before their index date; (D) were age ≥50 years at their index date; (E) had at least 
two years of eligible CPRD data before their index date; (F) had an index date before the end of 
the eligible CPRD data; and (G) survived and were otherwise eligible for follow-up one year 
after cancer diagnosis.  Patients were required to have been age ≥50 years at their index date 
because diabetes in older adults is linked to higher mortality, (31) and because older adults 
with diabetes are at substantial risk for both acute and chronic microvascular and 
cardiovascular complications (32).  Men with breast cancer were excluded.  Read codes from 
the Department of Health, Data and Business (QOF) Rules, Cancer and Diabetes Indicator Sets, 
version 25.0, (33) were used to identify diabetes and cancer in CPRD.  
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Control selection: matching 
Each cancer patient (case) was matched to up to four non-cancer patients (controls) with pre-
existing diabetes on GP practice number, sex (colorectal only), and age (±1 year) at cancer 
diagnosis.  Matched controls were also required to have met inclusion criteria D–G above.   In 
addition to the three cohorts of breast, colorectal, and prostate cancer patients plus non-cancer 
controls, a fourth cohort was constructed by combining the three individual cohorts. 
Patients were followed up to 10 years after their index date for new microvascular and 
macrovascular complications (as described below).  They were followed from one year after 
their index date up to 10 years for all-cause and diabetes mortality. 
Variables 
Diabetes Complications 
Complications of diabetes consisted of incident microvascular and macrovascular conditions 
(34) first identified in patients’ electronic health records up to 10 years after their index date.  
Microvascular conditions consisted of retinopathy, neuropathy, nephropathy, chronic kidney 
disease (Stage 4 or 5), and the composite outcome of any of the four above.  Macrovascular 
complications consisted of peripheral arterial disease, acute myocardial infarction or coronary 
syndrome, cerebrovascular accident, lower limb amputation, and the composite outcome of 
any of the four above.  Incident complications were identified using published lists of Read 
codes (35) present in patients’ records up to 10 years after their index date.  Those patients 
identified with a specific complication prior to their index date were excluded from the 
population at risk for that complication during follow-up. 
Mortality 
Variables were constructed for all-cause and diabetes mortality, which was defined as the 
presence of an International Classification of Diseases, 10th Revision, Clinical Modification (ICD-
10-CM) code in the ONS data indicating that the underlying cause of death was due to diabetes 
(ICD-10-CM E10-14), hyperglycaemia (R73), hypoglycaemia (E16.1, E16.2), myocardial infarction 
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(I21-I22), ischaemic heart disease (I20, I24, I25), stroke/sequelae (I60-I64, I69.0-I69.4), heart 
failure (I50), sudden death due to cardiac arrest (I46), peripheral vascular disease (I70-I74), or 
kidney disease (N00-N28). (36,37)  
Covariates 
Baseline characteristics consisted of age at index date, sex, calendar year of index date, most 
recent (before the index date) smoking status, most recent drinking status, and index of 
multiple deprivation quintile, from least deprived (=1) to most deprived (=5), body mass index 
(kg/m2) and Charlson Comorbidity Index. (38,39)   Baseline clinical and laboratory values 
consisted of blood pressure (mm Hg), total cholesterol (mmol/L), and glycosylated hemoglobin 
(HbA1c: mmol/mol), identified with the use of the most recent value within one year before the 
index date.  Categorical variables for laboratory values were constructed by using cutoffs that 
corresponded to the thresholds for meeting the laboratory-based performance indicators in the 
QOF Rules, Diabetes Indicator Set, version 25.0, (33): blood pressure ≤140/80 mm Hg, total 
cholesterol ≤5 mmol/L, and HbA1c ≤59, 59–≤64, 64–≤75, and >75 mmol/mol.  Baseline 
antidiabetic agents were identified with the use of British National Formulary codes in the CPRD 
therapy file (40) within one year before the index date.  
Statistical Methods 
Since there was a reasonable chance overall mortality would be higher in cancer patients than 
controls, we used competing risks regression according to the approach proposed by Fine and 
Gray (41) to estimate the cumulative incidence function and unadjusted and adjusted hazard 
ratios (HR) for each microvascular and macrovascular complication, comparing cancer patients 
to non-cancer controls.  Patients were censored at 10 years after their index date or at the end 
of their eligibility for follow-up in the data, whichever came first.  The competing risk was death 
prior to the date of censoring.  Adjusted analyses included baseline demographic and clinical 
covariates as described above.  Patients with a specific diabetes complication prior to their 
index date were excluded from that particular analysis.   
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Competing risks regression (41) also was used to estimate unadjusted and adjusted HRs for all-
cause and diabetes mortality.  Only patients eligible for linkage to the ONS data were included 
in the mortality analyses.  Also, since study inclusion criteria required patients to have survived 
at least one year after their index date, survival analyses included only years 2-10 of follow-up.  
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Results 
Overall, there were 14,517 patients in the combined cohort: 3,382 (23.3%) cancer patients and 
11,135 (76.7%) controls. (Table 1) There were no statistically significant differences in age, sex, 
and year of diagnosis between cancer patients and controls, because age and sex were used as 
matching criteria in constructing the cohorts, and controls received the same index date as 
their corresponding cases.  There were small but statistically significant (p ≤ 0.05) differences 
between cancer patients and controls in the distributions of smoking status, BMI, and Charlson 
Comorbidity Index. (Table 1) There were no differences between cancer patients and controls 
in mean baseline blood pressure or HbA1c.  Cancer patients had statistically significantly lower 
mean baseline total cholesterol than controls.   (Table 1) However, the absolute difference was 
only 0.1 mmol/L. 
The total number of years of follow-up in the combined cohort was 59,431, 13,372 (22.5%) of 
which were for cancer patients.  Overall, the median length of follow-up was 1,495 days (4.1 
years), and follow-up was statistically significantly shorter in cancer patients (median 1,444 
days) than in controls (median 1,511 days: log-rank test for equality of survivor functions, p < 
0.0001).   
Diabetes Complications 
There were no differences between cancer patients and controls in the adjusted rate of any 
microvascular or macrovascular complication, (Figure) either in the combined cohort or in any 
of the three cancer cohorts, (total of 80 unadjusted and adjusted comparisons) except that in 
the combined cohort, and only in the colorectal cancer cohort, cancer patients were less likely 
to develop retinopathy (adjusted HRs 0.88; 95%CI=0.79-0.98 and 0.81 95%CI=0.66-0.91 
respectively).  The results of sensitivity analyses in which a variable specifying the type of 
diabetes (Type I or Type II) was added to the list of predictors in the adjusted models were 
virtually identical to those reported above (results not shown). 
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Mortality 
All-cause mortality was statistically significantly higher in cancer patients than controls (Table 
3).  However, there was no evidence cancer adversely impacted diabetes-related mortality.  
Diabetes-related mortality was significantly lower among cancer patients in the combined 
cohort (adjusted HR 0.76; 95%CI=0.61-0.94) and in the prostate cancer cohort (adjusted HR 
0.61; 95%CI=0.43-0.88). (Table 3) The results of sensitivity analyses in which a variable 
specifying the type of diabetes (Type I or Type II) was added to the list of predictors in the 
models were virtually identical to those reported above (results not shown). 
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Discussion 
Evidence indicates pre-existing diabetes is associated with worse outcomes in several types of 
cancer.  However, there is less information on whether incident cancer is associated with worse 
diabetes outcomes.  This as an important gap because as the relative survival for many types of 
cancer continues to improve, overall survival depends increasingly on the quality and outcomes 
of care for other underlying conditions.  Overall, this study suggests that in the UK there is no 
reason to suspect that the outcomes of diabetes in the presence of cancer are adversely 
affected by the competing needs of cancer care.   
Among 80 unadjusted and adjusted comparisons of diabetes complications, we found no 
instance in which cancer was associated with higher incidence of a complication.  Cancer was 
associated with lower adjusted incidence of retinopathy in the colorectal cancer and the 
combined cohorts, but the reason for this is not immediately clear, and chance finding due to 
multiple testing cannot be ruled out.  As might be expected, cancer was associated with higher 
all-cause mortality even though we excluded patients who survived less than one year.  
However, there was no evidence of an adverse impact on diabetes-related mortality.  In fact, 
our findings suggest prostate cancer was associated with lower diabetes mortality in competing 
risks regression that accounted for death due to other causes. 
There are several possible reasons that we found no adverse associations between cancer and 
diabetes complications or mortality.  First, we were able to adjust for differences in baseline 
characteristics between diabetic cancer patients and diabetic non-cancer controls that 
otherwise could have confounded associations between cancer and diabetes outcomes.  These 
included baseline BMI, smoking status, HbA1c, cholesterol, and blood pressure.  Second, our 
study was conducted in the UK, which has a robust primary care system in which, under the 
Quality and Outcomes Framework, (33) there are financial incentives for GPs to provide high 
quality diabetes care throughout the continuum of care for other conditions such as cancer. 
Our study has several strengths, which are attributable largely to the high quality of the 
database we used.  Notably, because the study was based on CPRD, we were able to adjust for 
additional clinical factors typically not available in US health insurance claims databases, which 
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otherwise may have confounded associations between cancer and the outcomes of diabetes.  
These included baseline BMI, smoking status, blood pressure, cholesterol, and HbA1c.  In 
addition, we had rich data about clinical outcomes over a relatively long period of time.  Our 
study also has several limitations.  First, at the time it was conducted, we were unable to link 
the CPRD data to information from the National Cancer Intelligence Network (NCIN), which 
would have given us details on cancer stage and initial treatment.  Although primary care data 
have a high sensitivity and specificity for identifying cancer (42), registry data would have 
allowed us to exclude cancer patients diagnosed with metastatic disease.  We considered using 
Read codes in the primary care data files or ICD-10 codes in the Hospital Episode Statistics (HES) 
inpatient data to stage patients.  However, we are not aware of any studies in the UK that 
validate the use of ICD-10 codes for this purpose, and because only two-thirds of the patients in 
our study were linked to HES, doing so would have limited our sample sizes for all the analyses.  
Instead, we excluded patients who died within the first year after their index date.  Second, 
since we did not have access to cancer treatment data we were unable to identify subgroups of 
cancer patients who may have been at higher risk of diabetes complications or related mortality 
due to the cancer treatment they received.  This should be the subject of further research once 
linkage to NCIN and chemotherapy databases becomes more readily available.  Third, although 
we required all patients to have survived at least one year after their index date, requiring 
longer survival might have enabled us to better assess the longer-term effects of cancer 
treatment among the cancer patients.  Finally, our findings may not be generalizable to long-
term survivors of breast, colorectal, and prostate cancer in an era of full implementation of 
QOF, which was designed to improve the quality of diabetes primary care, to other countries 
that do not have primary care performance measures for diabetes care in place, or to other 
types of cancers. 
Conclusions  
Overall, incident cancer appears to have had little adverse impact on the long-term outcomes 
of pre-existing diabetes during 10 years after a diagnosis of breast, colorectal, or prostate 
cancer.  These findings are important for cancer survivors with pre-existing diabetes because 
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they suggest that the advances in cancer therapy and supportive care, which have substantially 
improved the relative survival of many of the most common types of cancer, are not 
undermined by excess diabetes morbidity and mortality. 
  
14 
 
 
Compliance with Ethical Standards 
Funding: This study was funded by the Population Research Committee, Cancer Research UK.  
Quality and Outcomes of Care for Chronic Conditions in Older Patients Diagnosed with Breast, 
Colorectal, or Prostate Cancer Compared to Non-Cancer Controls:  An Observational Study 
Using the Clinical Practice Research Datalink (CPRD).  Reference # 16609. 1 July 2013–29 
February, 2016.  In addition, Dr. Keating is supported by K24CA181510 from the US National 
Cancer Institute. 
 
Conflict of Interest:  All authors declare that they have no conflicts of interest. 
 
Ethical Approval:  This article does not contain any studies with human participants or animals 
performed by any of the authors.  The protocol for this study was approved by the Independent 
Scientific Advisory Committee (ISAC) to the CPRD on 1 August 2013 (ISAC reference number 
13_124) with subsequent amendments approved by ISAC on 22 May 2014.  Changes relevant to 
analyses presented here include identification of diabetes complications through the primary 
care record, as described above, rather than from hospital data; this change was made because 
hospital data linkage was not available in all patients.  The ISAC protocol was made available to 
the reviewers and editors during the peer-review process. 
 
Contributions 
Guarantor:  RIG takes full responsibility for the work as a whole, including the study design, 
access to data, and the decision to submit and publish the manuscript. 
 
Author Contributions: All authors contributed to the conception and design of the work.  RIG 
and ECM acquired the data.  RIG and ECM performed the analyses.  All authors contributed to 
the interpretation of the data for the work.  RIG drafted the manuscript.  All authors 
contributed to revising it critically for important intellectual content.  
  
15 
 
 
References 
1. Giovannuci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, 
Regensteiner JG, Yee D.  Diabetes and cancer: a consensus report.  Diabetes Care 2010; 
33(7):1674-1685. 
2. Mills KT, Bellows CF, Hoffman AE, Kelly TN, Gagliardi G. Diabetes and colorectal cancer 
prognosis: a meta-analysis. Dis Colon Rectum, 2013;56(11):1304-1319. 
3. De Bruijn KMJ, Arends LR, Hansen BE, Leeflang S, Ruiter R, van Eijck CHJ. Systematic 
review and meta-analysis of the association between diabetes mellitus and incidence 
and mortality in breast and colorectal cancer.  British Journal of Surgery 2013;100:1421-
1429. 
4. Peairs KS, Barone BB, Snyder CF, Yeh H-C, Stein KB, Derr RL, Brancati FL, Wolff AC.  
Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J 
Clin Oncol 2011;29:40-46. 
5. Jiang Y, Ben Q, Shen H, Lu W, Zhang Y, Zhu J.  Diabetes mellitus and incidence and 
mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies.  
Eur J Epidemiol 2011;26:863-876. 
6. Luo W, Cao Y, Liao C, Gao F.  Diabetes mellitus and the incidence and mortality of 
colorectal cancer: a meta-analysis of 24 cohort studies. Colorectal Disease 
2011;14;1307-1312. 
7. Stein KB, Snyder CF, Barone BB, Yeh H-C, Peairs KS, Derr RL, Wolff AC, Brancati FL.  
Colorectal cancer outcomes, recurrence, and complications in persons with and without 
diabetes mellitus: a systematic review and meta-analysis.  Dig Dis Sci 2010;55:1839-
1851. 
8. Snyder CF, Stein KB, Barone BB, Peairs KS, Yeh H-C, Derr RL, Wolff AC, Carducci MA, 
Brancati FL.  Does pre-existing diabetes affect prostate cancer prognosis?  A systematic 
review.  Prostate Cancer and Prostatic Diseases 2010;13:58-64. 
9. Barone BB, Yeh H-C, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL.  
Postoperative mortality in cancer patients with preexisting diabetes: systematic review 
and meta-analysis. Diabetes Care 2010;33(4):931-939. 
16 
 
 
10. Barone BB, Yeh H-C, Snyder CF, Pearis KS, Stein KB, Derr RL, Wolff AC, Brancati FL.  
Loong-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a 
systematic review and meta-analysis.  JAMA 2008;300(23):2754-2764. 
11. Psarakis HM. Clinical challenges in caring for patients with diabetes and cancer.  
Diabetes Spectrum 2006;19(3):157-162. 
12. Keating NL, Liu P-H, O’Malley AJ, Freedland SJ, Smith MR.  Androgen deprivation therapy 
and diabetes control among diabetic men with prostate cancer.  Eur Urol 
2014;65(4):816-824. 
13. Hershey DS, Tipton J, Given B, Davis E.  Perceived impact of cancer treatment on 
diabetes self-management.  The Diabetes Educator 2012;38(6):779-790. 
14. Snyder CF, Frick KD, Herbert RJ, Blackford AL, Neville BA, Wolff AC, Carducci MA, Earle 
CC. Quality of care for comorbid conditions during the transition to survivorship: 
differences between cancer survivors and noncancer controls. J Clin Oncol 
2013;31(9):1140-1148. 
15. Khan NF, Mant D, Rose PW. Quality of care for chronic diseases in a British cohort of 
long-term cancer survivors.  Ann Fam Med 2011;8(5):418-424. 
16. Chiao EY, Nambi PV, Naik AD. The impact of diabetes process and outcome quality 
measures on overall survival in patients with co-morbid colorectal cancer.  J Cancer 
Surviv 2010;4(4):381-387. 
17. Hanchate AD, Clough-Gorr KM, Ash AS, Thwin SS, Silliman RA.  Longitudinal patterns in 
survival, comorbidity, healthcare utilization and quality of care among older women 
following breast cancer diagnosis.  J Gen Intern Med 2010;25(10):1045-1050. 
18. Keating NL, Zaslavsky AM, Herrinton LJ, Selby JV, Wolf RE, Ayanian JZ. Quality of 
diabetes care among cancer survivors with diabetes.  Medical Care 2007;45(9):869-875. 
19. Earle CC, Neville BA.  Under use of necessary care among cancer survivors. Cancer 
2004;101(8):1712-1719. 
 
17 
 
 
20. Bayliss EA, Blatchford PJ, Newcomer SR, Steiner JF, Fairclough DL. The effect of incident 
cancer, depression and pulmonary disease exacerbations on type 2 diabetes control.  J 
Gen Intern Med 2011;26(6):575-581. 
21. Cancer Research UK. Cancer survival for common cancers. 
http://www.cancerresearchuk.org/health-professional/cancer-
statistics/survival/common-cancers-compared#undefined. Accessed 2/2016. 
22. Ning Yi, Shen Qin, Herrick K, Mikkelsen R, Anscher M, Houlihan R, Lapane K.  Cause of 
death in cancer survivors. Cancer Res 2012;72(8 Suppl): Abstract nr LB-339.  
23. Cancer Research UK. Longer cancer survival means nearly half of cancer patients die 
from other diseases. http://www.cancerresearchuk.org/about-us/cancer-news/news-
report/2012-04-03-longer-cancer-survival-means-nearly-half-of-cancer-patients-die-
from-other-diseases?view=rss. Accessed 2/2016. 
24. Macmillan Cancer Support.  Throwing light on the consequences of cancer and its 
treatment. July 2013.  http://www.ncsi.org.uk/wp-
content/uploads/MAC14312_CoT_Throwing-light_report_FINAL.pdf. Accessed 2/2016 
25. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, Smeeth L. Data 
Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015;44(3): 
827–836. 
26. Khan NF, Mant D, Carpenter L, Forman D, Rose PW.  Long-term health outcomes in a 
British cohort of breast, colorectal and prostate cancer survivors: a database study.  
British Journal of Cancer 2011;105:S29-S37. 
27. Taylor KS, Heneghan CJ, Farmer AJ, Fuller AM, Adler AI, Aronson JK, Stevens RJ.  All-
cause and cardiovascular mortality in middle-aged people with type 2 diabetes 
compared with people without diabetes in a large U.K. primary care database.  Diabetes 
Care 2013;36(8):2366-2371. 
28. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins 
MR, Majeed A, Elliott P.  Risk of cardiovascular disease and all cause mortality among 
patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort 
study using UK general practice research database.  BMJ 2009;339:b4731. 
18 
 
 
29. Redaniel MTM, Jeffreys M, May MT, Ben-Shlomo Y, Martin RM.  Associations of type 2 
diabetes and diabetes treatment with breast cancer risk and mortality: a population-
based cohort study among British women.  Cancer Causes Control 2012;23:1785-1795. 
30. Salisbury C, Johnson L, Purdy S, Valderas JM, Montgomery AA.  Epidemiology and impact 
of multimorbidity in primary care: a retrospective cohort study.  British Journal of 
General Practice 2011;61(582):e12-e21. 
31. Brown AF, Mangione CM, Saliba D, Sarkisian CA: Healthcare Foundation/American 
Geriatrics Society Panel on Improving Care for Elders with Diabetes.  Guidelines for 
improving the care of the older person with diabetes mellitus.  J Am Geriatr Soc 
2003;51(Suppl. Guidelines):S265-S280. 
32. Kirkman MS, Jones Briscoe V, Clark N, Florez H, Haas LB, Halter JB, Huang ES, 
Korytkowski MT, Munshi MN, Soule Odegard P, Pratley RE, Swift CS. Diabetes in older 
adults.  Diabetes Care 2012;35:2650-2664. 
33. Primary Care Commissioning (PCC) QOF Business Rules v25. http://www.pcc-
cic.org.uk/article/qof-business-rules-v25.0 Accessed 2/2016. 
34. Adler AI, Stratton IM, Neil HAW, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, 
Holman RR on behalf of the UK Prospective Diabetes Study Group.  Association of 
systolic blood pressure with macrovascular and microvascular complications of type 2 
diabetes (UKPDS 36): prospective observational study.  BMJ 2000:321:412-419. 
35. Kontopantelis E, Springate DA, Reeves D, Ashcroft DM, Rutter M, Buchan I, Doran T. 
Glucose, blood pressure and cholesterol levels and their relationships to clinical 
outcomes in type 2 diabetes: a retrospective cohort study. Diabetologia 2015;58(3):505-
518.  
36. Australian Institute of Health and Welfare. http://www.aihw.gov.au/diabetes-
indicators/deaths/. Accessed January 19, 2016. 
37. Ricci-Cabello I, Stevens S, Kontopantelis E, Dalton ARH, Griffiths RI, Campbell JL, Doran T, 
Valderas JM.  Impact of the Prevalence of Concordant and Discordant Conditions on the 
Quality of Diabetes Care in Family Practices in England.  Ann Fam Med 2015;13:514-522. 
19 
 
 
38. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic 
comorbidity in longitudinal studies: development and validation.  J Chronic Dis 
1987;40(5):373-383. 
39. Khan NF, Perera R, Harper S, Rose PW. Adaptation and validation of the Charlson Index 
for Read/OXMIS coded databases. BMC Fam Pract 2010;11(1).  
40. Dave S, Petersen I.  Creating medical and drug code lists to identify cases in primary care 
databases. Pharmacoepidemiol Drug Saf 2009;18(8):704-707.  
41. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing 
risk.  Journal of the American Statistical Association 1999;94(446):496-509. 
42. Boggon R, van Staa TP, Chapman M, Gallagher AM, Hammad TA, Richards MA. Cancer 
recording and mortality in the General Practice Research Database and linked cancer 
registries. Pharmacoepidemiol Drug Saf 2013;22:168-175. 
 
 
 
 
 
 
 
 
  
20 
 
 
Figure title and legend 
Title.  Cumulative incidence of microvascular and macrovascular complications.  
Legend. *Microvascular complications consisted of retinopathy, neuropathy, nephropathy, or 
chronic kidney disease (Stage 4 or 5).  Macrovascular complications consisted of peripheral 
arterial disease, acute myocardial infarction or coronary syndrome, cerebrovascular accident, 
or lower limb amputation. Cancer patients (red) and controls (blue).  
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Table 1: Patient Characteristics – Combined Cohorts 
 
 Combined Cohorts  
 Cancer (n=3,382) Control (n=11,135) All (n=14,517)  
 n % n % n % P-Value 
Age        
50-<60  248  7.3  800  7.2  1,048  7.2 0.740 
60-<70  946  28.0  3,098  27.8  4,044  27.9  
70-<80  1,498  44.3  5,041  45.3  6,539  45.0  
≥80  690  20.4  2,196  19.7  2,886  19.9  
Sex        
Male  1,974  58.4  6,551  58.8  8,525  58.7 0.630 
Female 1,408  41.6  4,584  41.2  5,992  41.3  
Year of Diagnosis        
2000-2004  546  16.1  1,649  14.8  2,195  15.1 0.087 
2005-2009  1,500  44.4  4,902  44.0  6,402  44.1  
≥2010  1,336  39.5  4,584  41.2  5,920  40.8  
Smoking Status        
Non Smoker  991  29.3  3,364  30.2  4,355  30 <0.001 
Ex Smoker  1,716  50.7  5,633  50.6  7,349  50.6  
Current Smoker  324  9.6  1,240  11.1  1,564  10.8  
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Not Reported  351  10.4  898  8.1  1,249  8.6  
Body Mass Index         
<25  579  17.1  1,932  17.4  2,511  17.3 <0.001 
25-<30  1,272  37.6  4,183  37.6  5,455  37.6  
≥30  1,344  39.7  4,656  41.8  6,000  41.3  
Not Reported  187  5.5  364  3.3  551  3.8  
Charlson Comorbidity Index         
1-2  1,878  55.5  5,898  53.0  7,776  53.6 0.024 
3-4  1,044  30.9  3,578  32.1  4,622  31.8  
>4  460  13.6  1,659  14.9  2,119  14.6  
Type of Cancer (or Control)        
Breast 1,036 30.6 3,194 28.7 4,230 29.1 <0.001 
Colorectal 1,069 31.6 4,047 36.3 5,116 35.2  
Prostate 1,277 37.8 3,894 35.0 5,171 35.6  
Type of Diabetes        
Type I 141 4.2 554 5.0 695 4.8 0.054 
Type II 3,241 95.8 10,581 95.0 13,822 95.2  
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Any Microvascular Complication        
No  2,412  71.3  7,750  69.6  10,162  70.0 0.056 
Yes  970  28.7  3,385  30.4  4,355  30.0  
Any Macrovascular Complication        
No  2,681  79.3  8,684  78.0  11,365  78.3 0.113 
Yes  701  20.7  2,451  22.0  3,152  21.7  
Any Antidiabetic Agent        
No  769  22.7  2,363  21.2  3,132  21.6 0.060 
Yes  2,613  77.3  8,772  78.8  11,385  78.4  
Blood Pressure ≤ 140/80 mm Hg        
Yes  2,026  59.9  6,770  60.8  8,796  60.6 <0.001 
No  1,250  37.0  4,252  38.2  5,502  37.9  
Not Reported  106  3.1  113  1.0  219  1.5  
        
Systolic mean(SD)  3,276  136(15)  11,022  136(16)  14,298 
 136(16) 0.205 
        
Diastolic mean(SD)  3,276  74(9)  11,022  74(9)  14,298  74(9) 0.090 
Total Cholesterol ≤ 5mmol/L        
Yes  2,706  80.0  8,971  80.6  11,677  80.4 <0.001 
No  475  14.0  1,826  16.4  2,301  15.9  
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Not Reported  201  5.9  338  3.0  539  3.7  
        
mean(SD)  3,181  4.2(0.94)  10,797  4.3(1.57)  13,978  4.2(1.45)
 <0.001 
HbA1c(mmol/mol)         
≤59  2,179  64.4  6,995  62.8  9,174  63.2 0.362 
59-≤64  310  9.2  1,054  9.5  1,364  9.4  
65-≤75  322  9.5  1,074  9.6  1,396  9.6  
>75  185  5.5  702  6.3  887  6.1  
Not Reported  386  11.4  1,310  11.8  1,696  11.7  
        
mean(SD)  2,996  54.0(12.5)  9,825  54.5(13.1)  12,821  54.3(13.0) 0.060 
 
 
SD  Standard Deviation; HbA1c Glycosylated hemoglobin  
Table 2:  Multivariate Analyses of Complications 
   Cohort 
 Combined Breast Colorectal Prostate 
Type of Complication Unadjusted Hazard Ratio [95% CI] Adjusted Hazard Ratio [95% CI]
 Unadjusted Hazard Ratio [95% CI] Adjusted Hazard Ratio [95% CI] Unadjusted 
Hazard Ratio [95% CI] Adjusted Hazard Ratio [95% CI] Unadjusted Hazard Ratio [95% CI]
 Adjusted Hazard Ratio [95% CI] 
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Any Microvascular 0.96 0.99 1.03 1.04 1.01 1.02 0.89 0.94 
 [0.87-1.06] [0.89-1.09] [0.86-1.23] [0.86-1.25] [0.85-1.20] [0.85-1.22]
 [0.76-1.05] [0.80-1.11] 
Chronic Kidney Disease 1.08 1.13 1.23 1.22 0.94 1.05 1.01 1.11 
 [0.85-1.36] [0.89-1.43] [0.83-1.82] [0.81-1.82] [0.62-1.44] [0.68-1.64]
 [0.68-1.51] [0.74-1.68] 
Nephropathy 1.12 1.19 1.16 1.19 1.71 1.82 0.65  
 [0.66-1.88] [0.70-2.02] [0.41-3.28] [0.41-3.45] [0.78-3.73] [0.83-3.98]
 [0.25-1.70]  
Neuropathy 1.07 1.10 1.22 1.23 1.31 1.30 0.83 0.84 
 [0.88-1.31] [0.90-1.35] [0.85-1.76] [0.85-1.78] [0.96-1.81] [0.94-1.80]
 [0.59-1.17] [0.59-1.18] 
Retinopathy 0.86** 0.88* 0.96 0.97 0.82 0.81* 0.83* 0.89 
 [0.77-0.96] [0.79-0.98] [0.79-1.17] [0.79-1.18] [0.67-1.00] [0.66-0.99]
 [0.69-0.99] [0.74-1.06] 
         
Any Macrovascular 0.94 0.96 1.04 1.00 0.92 0.94 0.93 0.98 
 [0.80-1.11] [0.82-1.13] [0.77-1.40] [0.74-1.37] [0.69-1.21] [0.71-1.24]
 [0.72-1.21] [0.75-1.26] 
Acute Myocardial Infarction 1.09 1.11 0.82 0.79 1.42 1.37 1.03 1.12 
 [0.87-1.37] [0.88-1.39] [0.50-1.32] [0.48-1.29] [0.99-2.04] [0.94-1.99]
 [0.72-1.49] [0.77-1.62] 
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Cerebrovascular Accident 0.99 0.99 1.33 1.42 0.90 0.97 0.87  
 [0.78-1.25] [0.78-1.26] [0.87-2.03] [0.92-2.17] [0.59-1.37] [0.64-1.47]
 [0.59-1.28]  
Lower Limb Amputation 0.76 0.83 0.51 0.45 1.18 1.21 0.55 0.62 
 [0.45-1.29] [0.49-1.42] [0.11-2.28] [0.10-2.09] [0.56-2.49] [0.53-2.74]
 [0.23-1.31] [0.25-1.52] 
Peripheral Arterial Disease 0.74* 0.78 0.99 0.94 0.60* 0.66 0.79 0.86 
 [0.56-0.97] [0.59-1.03] [0.56-1.74] [0.52-1.72] [0.36-1.00] [0.39-1.10]
 [0.52-1.18] [0.57-1.30] 
         
 
 
         
 
CI Confidence Interval 
*P <0.05- **P <0.01- ***P <0.001 
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Table 3:  Multivariate Survival Analyses 
   Cohort 
 Combined Breast Colorectal Prostate 
 Unadjusted Hazard Ratio [95% CI] Adjusted Hazard Ratio [95% CI] Unadjusted 
Hazard Ratio [95% CI] Adjusted Hazard Ratio [95% CI] Unadjusted Hazard Ratio [95% CI]
 Adjusted Hazard Ratio [95% CI] Unadjusted Hazard Ratio [95% CI] Adjusted 
Hazard Ratio [95% CI] 
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Mortality         
         
All Cause 1.47*** 1.57*** 1.47** 1.52*** 1.64*** 1.71***
 1.44*** 1.60*** 
 [1.33-1.63] [1.41-1.74] [1.21-1.80] [1.24-1.85] [1.38-1.95] [1.43-2.04]
 [1.22-1.72] [1.35-1.91] 
Diabetes  0.73** 0.76*** 0.87 0.91 0.88 0.87 0.57** 0.61*** 
 [0.59-0.90] [0.61-0.94] [0.58-1.31] [0.59-1.40] [0.63-1.23] [0.62-1.23]
 [0.40-0.82] [0.43-0.88] 
 
* p < 0.05- ** p < 0.01- *** p <0.001 
 
